Institut National de La Recherche Agronomique (INRA), UMR1331 ToxAlim, Toulouse, France.
Institut National de La Recherche Agronomique (INRA), UMR1331 ToxAlim, Toulouse, France; Institut National de La Santé et de La Recherche Médicale (INSERM), UMR1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France.
Mol Cell Endocrinol. 2018 Aug 15;471:75-88. doi: 10.1016/j.mce.2017.07.035. Epub 2017 Jul 31.
The liver plays a central role in the regulation of fatty acid metabolism. Hepatocytes are highly sensitive to nutrients and hormones that drive extensive transcriptional responses. Nuclear hormone receptors are key transcription factors involved in this process. Among these factors, PPARα is a critical regulator of hepatic lipid catabolism during fasting. This study aimed to analyse the wide array of hepatic PPARα-dependent transcriptional responses during fasting. We compared gene expression in male mice with a hepatocyte specific deletion of PPARα and their wild-type littermates in the fed (ad libitum) and 24-h fasted states. Liver samples were acquired, and transcriptome and lipidome analyses were performed. Our data extended and confirmed the critical role of hepatocyte PPARα as a central for regulator of gene expression during starvation. Interestingly, we identified novel PPARα-sensitive genes, including Cxcl-10, Rab30, and Krt23. We also found that liver phospholipid remodelling was a novel fasting-sensitive pathway regulated by PPARα. These results may contribute to investigations on transcriptional control in hepatic physiology and underscore the clinical relevance of drugs that target PPARα in liver pathologies, such as non-alcoholic fatty liver disease.
肝脏在脂肪酸代谢的调节中起着核心作用。肝细胞对驱动广泛转录反应的营养素和激素非常敏感。核激素受体是参与这一过程的关键转录因子。在这些因素中,PPARα 是禁食期间肝脏脂质分解代谢的关键调节因子。本研究旨在分析禁食期间广泛的肝脏 PPARα 依赖性转录反应。我们比较了在进食(随意)和 24 小时禁食状态下,具有肝细胞特异性 PPARα 缺失的雄性小鼠及其野生型同窝仔鼠的肝脏基因表达。采集肝脏样本,并进行转录组和脂质组分析。我们的数据扩展并证实了肝细胞 PPARα 作为饥饿期间基因表达中央调节因子的关键作用。有趣的是,我们确定了新的 PPARα 敏感基因,包括 Cxcl-10、Rab30 和 Krt23。我们还发现,肝脏磷脂重塑是一种新的由 PPARα 调节的禁食敏感途径。这些结果可能有助于研究肝脏生理学中的转录控制,并强调了靶向 PPARα 的药物在肝脏疾病(如非酒精性脂肪性肝病)中的临床相关性。